ArticleOPEN ACCESS

AZALEA-TIMI 71 trial: less bleeding with abelacimab compared to rivaroxaban in atrial fibrillation, but stroke prevention is uncertain

European Heart Journal - Cardiovascular Pharmacotherapy
DOI: 10.1093/ehjcvp/pvaf008
1Citations
Citations of this article
4Readers
Mendeley users who have this article in their library.

This article is free to access.

Cite

CITATION STYLE

APA

Gragnano, F., Cesaro, A., Galli, M., & Calabrò, P. (2025, May 1). AZALEA-TIMI 71 trial: less bleeding with abelacimab compared to rivaroxaban in atrial fibrillation, but stroke prevention is uncertain. European Heart Journal - Cardiovascular Pharmacotherapy. Oxford University Press. https://doi.org/10.1093/ehjcvp/pvaf008

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free